https://www.optimumcomms.com/wp-content/uploads/2024/03/Asgard_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-14 08:09:382024-03-14 08:09:38Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology
https://www.optimumcomms.com/wp-content/uploads/2024/03/Asgard_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-14 08:09:382024-03-14 08:09:38Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology
Mission Therapeutics raises £25.2 million to progress clinical candidates in the area of mitophagy
• Developing novel therapeutics which enhance the removal of…

Biocomposites announces approval of STIMULAN in Brazil as an antibiotic carrier for treating bacterial infection
STIMULAN, when mixed with antibiotics, can be used for the…

Novo Holdings reports Total Income and Investment Returns of DKK 31 billion (€4.2 billion) for 2023. Total Assets grow by 38% to DKK 1,114 billion (€149 billion)
Copenhagen, Denmark – Novo Holdings today announced its financial…

US FDA grants Orphan Drug Designation for iOnctura’s first-in-class autotaxin cancer therapy
Autotaxin inhibitor, IOA-289, recently received the proposed…

BioInnovation Institute provides financial support as six promising companies enter the Venture House program
BioInnovation Institute (BII), an international non-profit foundation…

Novo Nordisk Foundation awarded more than DKK 9.1 billion for purposes benefitting society in 2023
Focusing its support on science, education, innovation and development…

Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm:…

Women in Life Science Denmark (WiLD) to host network meeting in collaboration with DANISH BIO to promote equity in the Danish life science industry
Keynote speaker Margrethe Vestager, EU commissioner and EVP of…

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases
Significant appointments of industry and academic experts…

Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
Ladenburg, Germany, 6 March 2024 – Heidelberg Pharma AG (FSE:…

Novo Holdings Venture Investments 2023 Newsletter: A record year advancing innovative therapies for patients
18 new portfolio investments
Five portfolio companies…

Fibrocor Therapeutics enters into research and development collaboration with McQuade Center for Strategic Research and Development to advance Alport Syndrome program
Agreement includes a single digit million US$ upfront payment…

Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials
First patent application registered
BRAIN Biotech relies…

Ariceum Therapeutics announces opening of new state-of-the-art laboratory in Berlin providing infrastructure for radiopharmaceutical development activities
Berlin, Germany, 5 March 2024 – Ariceum Therapeutics (Ariceum),…

Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
HealthCare Royalty to purchase royalties from worldwide sales…

4SC Files Marketing Authorisation Application with EMA for Resminostat (Kinselby)
Planegg-Martinsried, Germany, 1 March 2024 – 4SC AG (4SC,…

Ariceum Therapeutics Granted UK Authorisation to Conduct Phase I Clinical Study of its First-in-Class Iodine-123 Labelled PARP Inhibitor in Patients with Recurrent Glioblastoma
Berlin, Germany, 29th February 2024 – Ariceum Therapeutics…

Rare Disease Day 2024 – Call for greater awareness of X-linked adrenoleukodystrophy and cerebral adrenoleukodystrophy
Barcelona, Spain and Düsseldorf, Germany – 29 February, 2024 –…

Bionical Solutions Appoints Chief Technology Officer to Create Innovative Data Products and Software for the Digital Business
WILLINGTON, England, Feb. 29, 2024 - Bionical Solutions, a…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York